ReviewFrontiers in pharmacology2026
The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-COVID syndrome is predominantly characterized by persistent fatigue that cannot be attributed to other underlying diseases or relieved by conventional rest. Such symptoms may last for weeks to months, substantially impairing patients' health status and quality of life. Nevertheless, current understanding of the pathogenesis of post-COVID syndrome remains insufficient, posing major challenges to its effective clinical management. Therefore, this review elaborates comprehensively on the pathogenesis, potential therapeutic targets, and pharmacological interventions for post-COVID syndrome, aiming to provide evidence for drug research and development as well as clinical application. Four interrelated pathogenic mechanisms sustaining chronic inflammation after viral clearance are collectively involved in disease progression, including immune dysregulation accompanied by chronic low-grade inflammation, mitochondrial dysfunction and impaired energy metabolism, renin-angiotensin system imbalance, and gut microbiota dysbiosis with disrupted gut-brain axis function. Based on these mechanistic findings, this review highlights potential therapeutic targets such as TLR4/TLR7, the JAK/STAT pathway, the NLRP3 inflammasome, the AMPK/NRF2 axis, and the PINK1/Parkin pathway. Accordingly, we summarize mechanism-targeted candidate drugs, including Toll-like receptor antagonists, JAK inhibitors, probiotics, mitochondria-targeted agents and drugs correcting renin-angiotensin system imbalance. In addition, this review summarizes other therapeutic candidates acting via distinct mechanisms, such as fluvoxamine, coenzyme Q10 combined with alpha-lipoic acid, astragalus root extracts, other medicinal herbs and traditional Chinese compound formulas. Post-COVID syndrome represents a complex public health challenge. Further in-depth mechanistic research and rational application of emerging technologies are still required to develop therapeutic strategies for preventing and alleviating the onset and progression of post-COVID syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.